EFFECT OF OIL IN WATER AND ALUM ADJUVANTS ON THE POTENCY OF RECEPTOR BINDING DOMAIN BASED COVID-19 SUBUNIT VACCINE
Along with the spread of COVID-19 in various parts of the world, many parties are researching to create a vaccine to control the disease. They continue researching the COVID-19 vaccine according to the World Health Organization (WHO) recommendations. The use of adjuvants greatly affects the pot...
Saved in:
Main Author: | |
---|---|
Format: | Theses |
Language: | Indonesia |
Online Access: | https://digilib.itb.ac.id/gdl/view/73963 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Institut Teknologi Bandung |
Language: | Indonesia |
Summary: | Along with the spread of COVID-19 in various parts of the world, many parties are
researching to create a vaccine to control the disease. They continue researching
the COVID-19 vaccine according to the World Health Organization (WHO)
recommendations. The use of adjuvants greatly affects the potential value of
vaccines, especially subunit vaccines. Another challenge in vaccine development is
the cost of the vaccine, especially in developing countries like Indonesia. This study
was conducted to determine the effect of differences in oil in water (OIW) adjuvants
and aluminum adjuvants on the immune response along with the resulting cost
analysis using non-inferiority studies and cost analysis of the use of adjuvants
compared to the RBD vaccine, which already has a distribution permit in Indonesia
(RBD- CPGs/Alums). In this study, OIW was made independently using a
microfluidizer and AlPO4 with the stirring method, while Al(OH)3 was used directly
from the vendor. Formulations were made with various RBD ratios with adjuvants.
Potency was measured using ELISA against the serum of Bulb c mice immunized
via the intramuscular route twice. For statistical analysis, one-way ANOVA and
Geometric Mean Titer (GMT) were used to determine the best ratio of RBD and
adjuvant. Analysis of the cost ratio of RBD and the best adjuvant compared to RBD
vaccines that already have distribution permits. The study showed that RBD 25 µg
and 50 µg, formulated with OIW adjuvants, had the best immune response. The use
of OIW adjuvants costs 15 times lower than similar vaccines in circulation. The
formulation produced in this study has the potential to be developed on a larger
scale production.
|
---|